BIOTECHNOLOGY
Precision medicine involves treatments targeted to a person’s genetic makeup
which affects 20-30% of the population worldwide, with over 25% of the Scottish population believed to be affected. Death rates from chronic liver disease in Scotland are 70% higher than the UK average and 60% higher than 30 years ago. Liver disease affects people of working age with an estimated £7.3bn per year in lost productivity (UK).
Precision medicine will be key to creating a healthier nation
representing an opportunity for Scotland to benefit from increased productivity, jobs and economic growth. Furthermore, more effective targeted treatments and better prevention of disease will create a healthier and more productive workforce. One size definitely does not fit all when it comes to medicine. Some drugs work for a significant proportion of the population, but other treatments don’t work at all for many patients or cause unwanted side effects – a drug that is effective for one person could be ineffective or toxic to another. Current challenges faced by many countries include the increasing numbers of patients being diagnosed with liver disease. Tis is an area that Precision Medicine Scotland Innovation Centre (PMS-IC) identified as an area of unmet need globally – especially fatty liver disease,
UNLOCKING THE VALUE IN PATIENT DATA Precision Medicine Scotland Innovation Centre (PMS-IC) has developed a data commons called SteatoSITE that holds annotated and curated data allowing researchers from both academia and industry to utilise this resource to look for potential diagnostic biomarkers, identify possible treatment options and contribute to the development of a clinical decision support tool using AI.
Tis is just one of a number of diseases being worked on at the PMS-IC. Others include ovarian cancer, multiple sclerosis, rheumatoid arthritis and chronic obstructive pulmonary disease – both in terms of prevention and developing new treatments and understanding the disease. Data is key to this and Scotland is well placed to take advantage of the health information infrastructure PMS-IC has built. It is one of the best countries in the world in terms of having well-mapped patient data.
Coupled with world-renowned
universities and academics, and industry and clinical innovators, the life sciences sector in Scotland is thriving and PMS-IC is driving even greater collaboration to deliver new discoveries in precision medicine. Te team at PMS-IC is committed to ensuring that the right treatment gets to the right person at the right time. And that delivers both health and wealth.
Faster disease diagnostics will bring a boost to the nation’s health
Marian McNeil is chief executive, Precision Medicine Scotland Innovation Centre.
www.precisionmedicinescotland.com
www.scientistlive.com 39
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
